Please assess the completion status of the following clinical trial:

Trial Title: Hepatitis C Virus Donor Positive Kidney Transplantation for Hepatitis C Virus Negative Recipients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* No evidence of HCV infection by HCV PCR (done at the time of the initial consent)~* Age\>60 yrs with an expected waiting time\>2 years; or~* Age\<60 yrs with any one of the following risk factors: Diabetes, coronary artery disease, peripheral artery disease and/or cerebrovascular disease~* Willingness to provide informed consent~* Absence of a living donor.~Exclusion Criteria:~* Estimated life expectancy of less than one year based on clinical judgment of the investigator~* Prior liver or renal transplantation~* Pregnant women~* Incarcerated patients~* Medical or social condition which in the opinion of the investigator will interfere with or prevent follow-up per protocol~* Unable or unwilling to return for follow-up visits~Donor Exclusion Criteria:~* HBV sAg positive~* HIV PCR or antibody positive~* HCV RNA negative

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- HCV+ Donor Kidney Recipient (Type: EXPERIMENTAL): All HCV- participants who receive an HCV+ donor kidney transplant will receive a first 'on-call' dose of Epclusa (sofosbuvir/velpatasvir; Gilead) and then three more doses on post-operative Day 1, 2 and 3. Donor HCV Genotype data will be available by Day 7 of transplant.~Patients will then be followed by serial HCV PCRs. Patients who are HCV PCR positive by Day 14 will be treated with Epclusa once daily x 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).